Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

10.2K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.2K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

15.6K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.6K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

3.5K
3.5K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

6.4K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.4K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

9.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EpiATLAS - a reference for human epigenomic research.

bioRxiv : the preprint server for biology·2026
Same author

LCR-modules: a collection of workflows for cancer genome analysis.

Bioinformatics (Oxford, England)·2026
Same author

HNRNPU mutations redirect cell cycle control to E2F in MYC-driven lymphomas.

Blood advances·2026
Same author

Chronic lymphocytic leukemia with <i>IGH</i>::<i>BCL3</i>-translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape.

HemaSphere·2026
Same author

The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia.

Leukemia·2026
Same author

Aging cells, young patients: senescence in Hodgkin lymphoma.

Blood advances·2026

Related Experiment Video

Updated: Apr 11, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K

Genomic alterations underlying immune privilege in malignant lymphomas.

Anja Mottok1, Christian Steidl

  • 1aCentre for Lymphoid Cancer, BC Cancer Agency bDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

Current Opinion in Hematology
|June 8, 2015
PubMed
Summary

Malignant lymphomas evade immune surveillance through genomic alterations affecting antigen presentation and immune signaling pathways. Understanding these mechanisms is key to developing novel therapies targeting the tumor microenvironment.

More Related Videos

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.8K

Related Experiment Videos

Last Updated: Apr 11, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.8K

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Malignant lymphomas are diverse cancers with complex oncogenomes and clinical presentations.
  • Lymphoma cells employ strategies to subvert immune responses, gaining immune privilege.
  • Tumor microenvironment interactions are critical in lymphomagenesis and immune evasion.

Purpose of the Study:

  • To review genomic alterations enabling acquired immune privilege in lymphoid cancers.
  • To summarize current knowledge on immune evasion mechanisms in lymphoma.

Main Methods:

  • Review of recent literature on genomic alterations in lymphoma.
  • Analysis of next-generation sequencing data and pathway perturbations.
  • Focus on immune cell and microenvironment contributions.

Main Results:

  • Next-generation sequencing has revealed genetic alterations driving lymphomagenesis.
  • Genomic changes in CIITA and programmed death ligand loci facilitate immune evasion.
  • Mutations in JAK-STAT and NFκB pathways are implicated in immune reprogramming.

Conclusions:

  • Further research into synergistic immune escape mechanisms is needed.
  • Development of predictive biomarkers for novel therapies targeting the tumor microenvironment is a future direction.
  • Immunological checkpoint inhibition represents a promising therapeutic strategy.